ExoCan is the first exosomes based company in India working in the Oncodiagnostic and Therapeutics space. ExoCan is dedicated to build innovative technology platforms in the frontiers of exosomes research by using their propriety technologies. It aims to translate the clinical potential of these tiny vesicles for better management of cancers by employing cross-disciplinary approaches at the forefront of exosomes research. The company is building up a broad range of biofluids e.g. urine, saliva, blood based platforms suitable to end users and clinicians alike. This platforms offer following advantages over existing exosomes based technologies for cancer diagnosis:
1.Rapid, and sensitive method for enriching exosomes from biofluids
2. Enhanced selectivity of the test
3. High yield and precision
4. Choice based use of technology

The company has received Biotechnology Ignition Grant by DBT-BIRAC, GoI,  Exocan is founded by Aman Sharma who is persuing his Ph.D from NCCS, Pune

Website: http://www.exocanhealthcare.com/